← Back to Home

Could MRI contrast use less gadolinium? Phase 2 results support advancing manganese-based mangaciclanol to Phase 3

A blinded image review showed similar overall diagnostic preference for this experimental contrast agent and gadobutrol. Beyond imaging performance, however, whether it can reduce retention in the body and safety risks requires more complete clinical evidence.

By SURL BioNews

Contrast agents help make lesions clearer on magnetic resonance imaging (MRI); developing new formulations also requires addressing safety questions once the drug enters the body. GE HealthCare announced on November 19 that its experimental manganese-based contrast agent mangaciclanol met the primary endpoint in the Phase 2 stage of the LUMINA trial. The results support advancing to Phase 3, adding human study evidence for an option beyond gadolinium-based contrast agents.

The comparison focused on adults with known or highly suspected central nervous system lesions who required contrast-enhanced MRI. Participants received both mangaciclanol and the gadolinium-based contrast agent gadobutrol, and independent readers who did not know which agent had been used compared the images side by side. According to the results released by the company, the two agents performed similarly on the primary endpoint of “overall diagnostic preference.”

This measure reflects which set of images readers preferred as a basis for diagnosis; it cannot be directly interpreted as equal diagnostic accuracy for disease. The announcement did not report the number of Phase 2 participants, preference proportions for each group, confidence intervals, or detailed statistical decision criteria. The description “similar” alone therefore does not establish that the two agents met formal criteria for equivalence or noninferiority.

There is a clinical rationale for seeking alternative formulations. The U.S. Food and Drug Administration (FDA)-approved prescribing information for gadobutrol states that gadolinium may remain in the brain, bones, and other organs for months or years, and warns of the risk of nephrogenic systemic fibrosis in patients with acute kidney injury or severe chronic kidney disease. However, retention in the body and actual harm are different issues, and this does not mean that everyone who receives a gadolinium-based contrast agent will be harmed.

GE HealthCare said no safety concerns were identified following dosing in Phase 2 and that it had selected 0.1 millimoles per kilogram of body weight as the Phase 3 dose. This remains an interim observation, however. The announcement did not provide details of adverse events or the duration of follow-up, leaving insufficient evidence to assess rare risks or long-term safety, much less establish that the manganese-based formulation is safer than existing agents.

Next, Phase 3 will further evaluate imaging performance and safety for lesions in the central nervous system and other parts of the body. Mangaciclanol has not yet received marketing approval. This development establishes the dose and direction for further validation; becoming a clinical alternative will still require evidence addressing image quality, diagnostic use, and safety in humans.

References

  1. GE HealthCare